{"id":40680,"date":"2026-08-19T15:05:37","date_gmt":"2026-08-19T13:05:37","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=40680"},"modified":"2026-08-19T10:03:57","modified_gmt":"2026-08-19T08:03:57","slug":"enlicitid-der-erste-orale-pcsk9-inhibitor-zur-senkung-des-cholesterins-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2026\/enlicitid-der-erste-orale-pcsk9-inhibitor-zur-senkung-des-cholesterins-cme","title":{"rendered":"Enlicitid \u2013 der erste orale PCSK9-Inhibitor zur Senkung des Cholesterins [CME]"},"content":{"rendered":"<p>Mit Enlicitid (Lipfendra\u00ae in den USA; MSD) wurde erstmals ein oral einzunehmender PCSK9-Inhibitor zur Behandlung der \u201eHypercholesterin\u00e4mie, einschlie\u00dflich der heterozygoten famili\u00e4ren Hypercholesterin\u00e4mie (HeFH)\u201c von der US-amerikanischen Food and Drug Administration (FDA) zugelassen . Enlicitid k\u00f6nnte insofern ein Fortschritt in der lipidsenkenden Therapie sein, da bislang verf\u00fcgbare PCSK9-Inhibitoren subkutan injiziert werden m\u00fcssen (Alirocumab und Evolocumab alle [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mit Enlicitid (Lipfendra\u00ae in den USA; MSD) wurde erstmals ein oral einzunehmender PCSK9-Inhibitor zur Behandlung der \u201eHypercholesterin\u00e4mie, einschlie\u00dflich der heterozygoten famili\u00e4ren Hypercholesterin\u00e4mie (HeFH)\u201c von der US-amerikanischen Food and Drug Administration (FDA) zugelassen . Enlicitid k\u00f6nnte insofern ein Fortschritt in der lipidsenkenden Therapie sein, da bislang verf\u00fcgbare PCSK9-Inhibitoren subkutan injiziert werden m\u00fcssen (Alirocumab und Evolocumab alle [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,1272,1274,6415,6414,6413,71,453,498,456,65,1525,1522],"class_list":["post-40680","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-arteriosklerose","tag-cholesterin","tag-coralreef-hefh-studie","tag-coralreef-lipids-studie","tag-enlicitid","tag-herzinfarkt","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-pcsk9","tag-pcsk9-hemmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=40680"}],"version-history":[{"count":4,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40680\/revisions"}],"predecessor-version":[{"id":40693,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40680\/revisions\/40693"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=40680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=40680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=40680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}